About Us

Perosphere Pharma is a private clinical-stage company focused on developing rescue drugs.

Perosphere Pharma's lead investigational drug product candidate, ciraparantag (PER977), is an FDA Fast Track designated, intravenously administered small synthetic water soluble new molecular entity intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and low molecular weight heparin. Ciraparantag is undergoing Phase 2 clinical testing to evaluate its ability to re-establish normal blood coagulation in subjects anticoagulated with Daiichi Sankyo Co., Ltd.'s SavaysaTM/Lixiana® (edoxaban), Johnson & Johnson's and Bayer HealthCare AG's Xarelto® (rivaroxaban), Bristol-Myers Squibb Company's and Pfizer Inc.'s Eliquis® (apixaban), and Sanofi’s Lovenox® (enoxaparin sodium sub-cutaneous injection). Perosphere Pharma is located in Danbury, CT, USA.